Reports Q1 revenue $215.5M, consensus $212.2M. “The first quarter of 2019 was a very productive start to the year, with strong execution across all aspects of our business,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. “We continued our efforts to maximize the commercial and clinical potential of cabozantinib through the U.S. launch in advanced hepatocellular cancer in January, as well as the initiation of the COSMIC-313 study announced today.”
https://thefly.com/landingPageNews.php?id=2901299
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.